| Price | Lot Size | Issue Date | Issue Size |
|---|---|---|---|
| ₹ 181 to ₹ 191 | 75 | 29th Sep, 2025 –01st Oct, 2025 | ₹230 Cr |
Fabtech Technologies Ltd
Fabtech Technologies Limited is a global turnkey engineering solutions provider headquartered in India, specialising in pharmaceuticals, biotechnology, and healthcare projects. Backed by the 29-year legacy of the Fabtech Group, the company delivers end-to-end solutions for setting up aseptic manufacturing facilities, covering the entire project lifecycle from market analysis, disease profiling, design, engineering, procurement, and logistics to installation, commissioning, and regulatory certification. Incorporated in 2018 following a strategic demerger to enhance operational efficiency, Fabtech has rapidly built a strong track record, completing 51 projects across geographies including Subscribe Saudi Arabia, Egypt, Algeria, Bangladesh, Ethiopia, Sri Lanka, and the UAE, and maintaining a robust order book of Rs. 904 crores as of July 31, 2025. The company operates in over 62 countries, with a significant presence in key emerging economies such as India, Bangladesh, Egypt, Ethiopia, Kenya, Saudi Arabia, Morocco, Nigeria, Turkey, the UAE, and the USA. The company offers both comprehensive greenfield turnkey solutions and standalone services- such as equipment procurement, supply, and commissioning- leveraging its asset-light model, integrated procurement system, and strong contractor network to optimise cost, quality, and execution timelines. Its proprietary digital project management platform, FabAssure, enhances efficiency through real-time monitoring, automation, and escalation mechanisms. With ISO 9001:2015, ISO 14001:2015, and ISO 45001:2018 certifications, a team of 94 qualified engineers, and deep regulatory expertise, Fabtech has evolved beyond cleanroom and controlled environment projects to become a preferred partner for pharmaceutical and biotech manufacturers globally. Its strong customer relationships, technological capabilities, and focus on high-margin turnkey solutions position the company to capitalise on the growing global demand for resilient and cost-effective healthcare infrastructure.
Objective of the Fabtech Technologies Ltd IPO
The net proceeds from the fresh issue will be used towards the following purposes:
- Funding working capital requirements of the company;
- Pursuing inorganic growth initiatives through acquisitions;
- General corporate purposes.
Rationale To Fabtech Technologies Ltd IPO
Aleading turnkey pharma engineering partner with comprehensive service offerings
The company is a key turnkey engineering solutions provider with an established presence in the pharmaceutical capex space and a strong track record of execution. The company offers comprehensive, end-to-end services from disease profiling and feasibility studies to design, engineering, procurement, equipment supplies, installation, testing, commissioning, training, validation, and certification, enabling clients to set up controlled environment pharmaceutical, biotechnology, and healthcare facilities across geographies. Its ability to integrate disease-specific profiling into project planning ensures that new facilities are tailored to the healthcare needs of target markets, thereby enhancing the relevance and commercial viability of client investments. Fabtech’s in-house design and engineering capabilities, combined with its proprietary FabAssure digital project management platform, provide real-time monitoring, cost control, and streamlined execution, driving efficiency and reducing implementation risk. The company’s asset-light model, supported by a strategic network of related entities and third-party suppliers, enhances scalability, improves cash flows, and ensures quality control across equipment procurement and project delivery. With a robust order book and turnkey projects, Fabtech enjoys strong revenue visibility and operating leverage. Its proven execution capabilities, showcased by the completion of 51 projects across key emerging and developed markets such as Saudi Arabia, Egypt, Algeria, Bangladesh, Ethiopia, Sri Lanka, and the UAE, position it to capitalise on the growing global demand for pharmaceutical infrastructure and healthcare investments, particularly in regulated and emerging markets. Backed by its technology-driven approach, integrated procurement system, and deep domain expertise, Fabtech is well-placed to expand its customer base, sustain high-margin turnkey projects, and deliver consistent growth in an industry benefiting from rising healthcare spending and the push for self-reliant pharmaceutical manufacturing globally.
Asset-light and integrated business model for scalable growth
The company has a scalable, asset-light, and integrated business model that enhances profitability, capital efficiency, and execution capability. By strategically sourcing a majority of critical equipment through Related Entities and third party suppliers on an arm’s-length basis, the company avoids significant capital expenditure on manufacturing facilities or heavy machinery. This approach allows Fabtech to focus resources on high-value activities such as project execution, sales, and marketing, while ensuring strict control over equipment quality, delivery timelines, and cost efficiency. The involvement of Related Entities provides reliable access to key equipment and enables Fabtech to leverage economies of scale, negotiate favorable procurement terms, and maintain consistent quality standards, thereby safeguarding margins and reducing operational risk. Complementing this asset-light procurement strategy is Fabtech’s integrated in house model, which encompasses risk assessment, design and engineering, equipment procurement and supply, quality control, logistics, and project execution teams. This integrated approach allows the company to capture a larger share of the value chain, reduce dependence on external suppliers, and mitigate contractual risks associated with third party delays or quality lapses. Moreover, by partnering with a diverse and reliable network of equipment manufacturers and contractors, Fabtech can flexibly scale its resources in line with project demands, ensuring optimal asset utilisation and sustaining cash-light operations. This business model provides a competitive edge over peers that operate with capital-intensive structures and limited service offerings, positioning Fabtech to expand its turnkey engineering
solutions across geographies.
Valuation of Fabtech Technologies Ltd IPO
Fabtech Technologies Limited is a leading turnkey engineering solutions provider in the pharmaceutical, biotechnology, and healthcare infrastructure space. The company specialises in delivering end-to-end project solutions, including disease profiling, feasibility studies, design and engineering, equipment procurement, installation, testing, and commissioning. With a strong global presence spanning over 62 countries and a particular focus on emerging markets, Fabtech leverages its asset-light, integrated business model to execute projects efficiently while maintaining strict quality and regulatory standards. The company aims to capitalise on its strong project pipeline and global footprint by focusing on scalable, asset-light operations, which reduce capital intensity. The company’s strategy is centered on expanding its turnkey offerings, strengthening customer relationships in emerging markets, and enhancing operational efficiencies through its proprietary project management platform FabAssure. By maintaining close partnerships with related entities and trusted third-party equipment suppliers, Fabtech secures competitive pricing, ensures timely delivery, and minimises execution risks. On the financial front, the company has delivered healthy CAGR growth over FY2023–25 period, with Revenue/EBITDA/PAT CAGR of 29.8%/29.1%/46.2%. The company is well-positioned to capitalise on the structural growth of the pharmaceutical and healthcare infrastructure sector globally. Its focus on emerging economies, combined with its technology-driven project execution capabilities, provides a competitive edge in securing high-value projects. Its asset-light model enables strong cash generation and high operating leverage, while maintaining flexibility to scale operations based on project demand. The company’s order book provides healthy revenue visibility for the coming years, reducing dependency on new client acquisitions in the short term. At the upper price band of Rs 191, the company is valued at a P/E multiple of 13.3x FY25 earnings. We, thus, recommend a“SUBSCRIBE” rating for this issue.
What is the Fabtech Technologies Ltd IPO?
The initial public offer (IPO) of Fabtech Technologies Ltd offers an early investment opportunity in Fabtech Technologies Ltd . A stock market investor can buy Fabtech Technologies Ltd IPO shares by applying in IPO before All Fabtech Technologies Ltd shares get listed at the stock exchanges. An investor could invest in Fabtech Technologies Ltd IPO for short term listing gain or a long term.
How to apply for the Fabtech Technologies Ltd IPO through StoxBox?
To apply for the Fabtech Technologies Ltd IPO through StoxBox one can apply from the website and also from the app. Click here
When will the Fabtech Technologies Ltd IPO open?
Fabtech Technologies Ltd IPO is opening on 29th Sep 2025. Apply Now
What is the lot size of the Fabtech Technologiesk Ltd IPO?
The Lot Size of Fabtech Technologies Ltd IPO is 75 equity shares. Login to your account now.
When is the Fabtech Technologies Ltd allotment date?
The allotment Date for Fabtech Technologies Ltd IPO is 03rd Oct 2025. Login to your account now.
When is the Fabtech Technologies Ltd IPO listing date?
The listing Date for Fabtech Technologies Ltd IPO is 7th Oct 2025. Login to your account now
What is the minimum investment required for the Fabtech Technologies Ltd IPO?
In the Retail segment the minimum investment required is Rs. 14,325. Login to your account now
What is the maximum investment allowed for the Fabtech Technologies Ltd IPO?
In the Retail segment the maximum investment requirement is Rs. 1,86,225. Login to your account now
What are the risks associated with investing in the Fabtech Technologies Ltd IPO?
- The company has historically converted less than 11% of submitted proposals into actual orders over the past three financial years. A continued inability to generate new leads or convert them into confirmed orders for an extended period could materially and adversely impact its business operations, financial condition, results, growth prospects, and cash flows.
- The company, due to its limited operating history, may face challenges in competing effectively in the market. Moreover, the absence of an extensive track record makes it difficult to evaluate the company’s business performance and to predict its future operating results based on past performance.
- Thecompany’s current order book may not reflect its future performance. Projects included in the order book, as well as future projects, could be delayed, altered, or cancelled due to factors beyond the company’s control, which could materially and adversely impact its business, prospects, reputation, profitability, financial condition, and operating results.
When will the Fabtech Technologies Ltd IPO shares be credited to my Demat account?
The Fabteck Technologies Ltd IPO be credited to the account on allotment date which is 06th Oct 2025. Login to your account now
Where can I find the Fabtech Technologies Ltd IPO prospectus?
The prospectus of Fabteck technologies Ltd IPO prospectus can be find on the website of SEBI, NSE and BSE
